KOAA News511d
Colorado Springs housing market becoming more 'balanced' according to PPAR board president
New numbers from the Pikes Peak Association of Realtors (PPAR) show that there weren't any major shifts in the Colorado ...
Nonalcoholic Steatohepatitis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
Hosted on MSN8mon
Tempest falls after new trial data for liver cancer therapy
Tempest Therapeutics (NASDAQ:TPST) shares dropped Thursday after the company updated data from an ongoing trial designed to test its PPAR⍺ antagonist, amezalpat (TPST-1120), as a first-line ...
Nature4y
Highly potent PPAR-α agonist versus standard therapy in patients with lipid disorders
Fibrates are widely prescribed agonists of transcription factor peroxisome proliferator-activated receptor (PPAR)-α, and are used to treat patients with atherogenic dyslipidemia. These drugs ...
Nature2mon
Antidiabetes wars: a new hope
A family of agonist drugs for peroxisome proliferator–activated receptor (PPAR-γ) is used in the clinic to battle insulin resistance for the treatment of type 2 diabetes. Their serious side ...
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced preclinical findings that highlight the potential of Glial Cell Line-Derived Neurotrophic Factor ...